Focus Stocks
Approaching Resistance: Sanofi-Aventis
Published on Friday, 25 January 2013 06:56 Written by TradersHuddle Wire
New York, January 25th (TradersHuddle.com) - Shares of Sanofi-Aventis (NYSE:SNY) are trading very close to calculated resistance at $49.28. The stock ended the trading session at just $48.50, which is near levels that make it difficult to buy or start a position.
Sanofi-Aventis (NYSE:SNY) is a global pharmaceutical company that researches, develops and manufactures prescription pharmaceuticals and vaccines. The Company develops cardiovascular, thrombosis, metabolic disorder, central nervous system, internal medicine and oncology drugs, and vaccines.
Sanofi-Aventis' stock range is defined by its calculated support defined at $42.75 and by the resistance level at $49.28; the stock is clearly over-extended from support, making it harder for participants to establish fresh longs.
Traders don't have a clear entry point for Sanofi-Aventis . However, as the stock pulls back towards $42.75 it will definitely provide a reference point to establish a trade. On the other hand, if the stock breaks above its resistance level at $49.28 then traders will get an opportunity to enter the stock as it moves to a higher range.
Related Articles
- Critical Alerts For Sanofi, Salesforce.com, AFLAC, HCA Holdings, and Silver Wheaton Released By InvestorsObserver
- Sanofi-Aventis Is Close to the 50 Day Moving Average
- Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
- Approaching Resistance: Sanofi-Aventis
- Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
- Football Legend Jerome Bettis & Sanofi US Tackle Anaphylaxis During National Asthma and Allergy Awareness Month
- Reference Points for Sanofi-Aventis
- Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
- Approaching Resistance: Sanofi-Aventis
- Sanofi-Aventis Is Close to Resistance
Related Partner Headlines
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi (SNY): Today's Featured Drugs Laggard - TheStreet.com
- Zalicus Prednisporin Licensee Sanofi Provides Update on Development Status - Benzinga
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi Reaches New 52-Week High (SNY) - TheStreet.com
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi To Buy Genfar - Benzinga
- Sanofi Stock Buy Recommendation Reiterated (SNY) - TheStreet.com
- Sanofi (SNY): Today's Featured Health Care Laggard - TheStreet.com
- Sanofi Reaches New 52-Week High (SNY) - TheStreet.com
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Technical Scans
-
Candlesticks – Hammer -
Near Both 50 and 200 Day - Stocks Trading Below 50 and Below The 200 -
Stocks Near 50 and 200 Day Moving Average Trading Above Both Moving Averages - With 50 day below the 200 -
Stocks Near 50 and 200 Day Moving Average Bullish Configuration 50 Above 200 Day -
Oversold Condition - Below Support
Latest Partner Headlines
-
Dow Today: Verizon Communications (VZ) Higher - TheStreet.com -
Separating the Bargains From the Busts - TheStreet.com -
Cramer Quick Take: The 60-Inch TV Will Be Key This Holiday - TheStreet.com -
Cramer Quick Take: Cisco Wins If Fiscal Cliff Is Resolved - TheStreet.com -
Gap Up and Sit - TheStreet.com -
Apple, Intel, MicroStrategy: Tech Winners & Losers - TheStreet.com -
Windows 8 PC Sales Disappointing: Report - TheStreet.com -
Cramer Quick Take: Buy Home Depot and Lowe's - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:15,296.23 Trade time:11:37AM EDT Value change:▼10.94 (-0.07%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,649.71 Trade time:11:37AM EDT Value change:▼5.64 (-0.34%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:3,456.91 Trade time:11:37AM EDT Value change:▼6.39 (-0.18%)In The Wires
-
Ridgeline Announces New Texas Facility Installation -
Stephan Beringer And Anthony Lye Expand Roles Within Publicis Groupe's Digital Technologies Division -- DigitasLBi And Razorfish -
VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials -
Ball Corporation Announces Early Tender Results Of Cash Tender Offer And Related Consent Solicitation -
Pharmagen To Present At The Second Annual Marcum LLP MicroCap Conference -
Ryan & Maniskas, LLP Announces Investigation of SoundBite Communications, Inc. -
Experience Miami Romance Month at Residence Inn Miami Airport -
Experience the Chicago Blues Festival and Stay Within Walking Distance at Renaissance Chicago Downtown Hotel








